PharmaPatents Timely Insight on Emerging Legal Developments

Tag Archives: Pegasys

India IP Board Invalidates Roche Hepatitis C Patent, Cites KSR

Posted in International Patent Practice

In a decision issued November 2, 2012, the Intellectual Property Appellate Board of India (IPAB) determined in a post-grant opposition proceeding that Roche’s patent covering its Pegasys® (pegylated interferon alfa-2a) product for the treatment of Hepatitis C, is invalid as obvious. The IPAB determined that an NGO had standing to challenge the patent, and cited U.S. case law, including KSR, in support of its decision.Continue reading this entry